ACADIA Pharmaceuticals Inc.
ACAD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $4 | $3 | $3 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $3 | $3 | $3 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 5.3% | 8.3% | -5.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 92.2% | 92.2% | 91.7% | 91.6% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 17.1% | 13.3% | 9.1% | 4.7% |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 25.8% | 10.1% | 7.8% | 55.4% |
| EPS Diluted | 0.42 | 0.16 | 0.11 | 0.86 |
| % Growth | 162.5% | 45.5% | -87.2% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | $0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | -$0 | $0 |